SG11201911598WA - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis - Google Patents

Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Info

Publication number
SG11201911598WA
SG11201911598WA SG11201911598WA SG11201911598WA SG11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA
Authority
SG
Singapore
Prior art keywords
endometriosis
gonadotropin
treatment
releasing hormone
dosing regimens
Prior art date
Application number
SG11201911598WA
Other languages
English (en)
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of SG11201911598WA publication Critical patent/SG11201911598WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201911598WA 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis SG11201911598WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
SG11201911598WA true SG11201911598WA (en) 2020-01-30

Family

ID=62620835

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911598WA SG11201911598WA (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Country Status (12)

Country Link
US (2) US11980621B2 (https=)
EP (1) EP3634418A1 (https=)
JP (2) JP7348171B2 (https=)
KR (2) KR102839190B1 (https=)
CN (1) CN110996956A (https=)
AU (2) AU2018280742B2 (https=)
CA (1) CA3066190A1 (https=)
EA (1) EA201992612A1 (https=)
MA (1) MA49256A (https=)
MX (1) MX2019014483A (https=)
SG (1) SG11201911598WA (https=)
WO (1) WO2018224498A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
AU2020325655B2 (en) * 2019-08-08 2025-09-11 Kissei Pharmaceutical Co., Ltd. Compositions and methods for the treatment of estrogen-dependent disorders
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
EP4243829A1 (en) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN116940575A (zh) * 2021-02-23 2023-10-24 深圳市康哲药业有限公司 噻吩并嘧啶二酮类化合物及其应用
CN115232144B (zh) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 含氮稠环类衍生物、药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
US7109171B2 (en) 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
US6960591B2 (en) 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
AU2004257639B2 (en) 2003-07-07 2011-01-06 Neurocrine Biosciences, Inc. Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
PL1939204T6 (pl) * 2005-10-19 2024-03-25 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
JP5337261B2 (ja) 2010-02-10 2013-11-06 キッセイ薬品工業株式会社 縮合複素環誘導体の塩及びその結晶
EA201491344A1 (ru) 2012-01-16 2015-04-30 Байер Интеллектуэль Проперти Гмбх Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
WO2013126517A1 (en) 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
WO2014038663A1 (ja) 2012-09-07 2014-03-13 アステラス製薬株式会社 スルホニルアミジン化合物の製造法
WO2014042176A1 (ja) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 縮合複素環誘導体の製造方法およびその製造中間体
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
AR095785A1 (es) 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
US9949974B2 (en) 2015-09-01 2018-04-24 Abbvie Inc. Methods of adminstering elagolix
UA123114C2 (uk) 2016-08-08 2021-02-17 Кіссеі Фармасьютікал Ко., Лтд. СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
SG11201911599XA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss
SG11202104053TA (en) 2018-11-07 2021-05-28 ObsEva SA Compositions and methods for the treatment of estrogen-dependent disorders

Also Published As

Publication number Publication date
JP7657855B2 (ja) 2025-04-07
MX2019014483A (es) 2020-08-17
WO2018224498A1 (en) 2018-12-13
CA3066190A1 (en) 2018-12-13
EP3634418A1 (en) 2020-04-15
JP2023113715A (ja) 2023-08-16
JP7348171B2 (ja) 2023-09-20
EA201992612A1 (ru) 2020-05-20
MA49256A (fr) 2021-05-26
CN110996956A (zh) 2020-04-10
US20200138819A1 (en) 2020-05-07
JP2020522571A (ja) 2020-07-30
KR20250117836A (ko) 2025-08-05
AU2018280742A1 (en) 2020-01-30
KR20200027481A (ko) 2020-03-12
US20240293414A1 (en) 2024-09-05
AU2024201701A1 (en) 2024-04-04
AU2018280742B2 (en) 2023-12-21
US11980621B2 (en) 2024-05-14
AU2024201701B2 (en) 2025-04-10
KR102839190B1 (ko) 2025-07-28

Similar Documents

Publication Publication Date Title
SG11201911598WA (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
IL271222A (en) Dosing regimens for anti-tim-3 antibodies and their uses
IL275238A (en) A liquid compound containing antagonistic VEGF
IL314891B2 (en) Dosage regimens and related compositions and methods
SI3347054T1 (sl) Režimi doziranja konjugatov zdravil proti TF protitelesu
ZA201900777B (en) Usage and dosage of therapeutic agents for endometriosis
IL253247A0 (en) Dosing regimen for madcam antagonists
GB201713653D0 (en) Dosage regimen
IL281968A (en) Dosage regimen for TFPI antagonists
IL272864A (en) A therapeutic agent containing an IL-33 antagonist for the treatment of endometriosis
GB201521217D0 (en) Dosage regimens
IL273419A (en) Dosage regimens of siphonimod
IL264139A (en) Dosing regimens of LINGO-1 antagonists and uses for the treatment of demyelinating disorders
GB201511126D0 (en) Spray device for the delivery of therapeutic agents
IL273382A (en) Dosage regimens of siphonimod
IL252903A0 (en) cgrp antagonist peptides
PT3406137T (pt) Dispositivo de dosagem
IL254593A0 (en) Combination dosage form of mu opioid receptor antagonist and opioid agent
HK40027582A (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
GB201614179D0 (en) Dosage regimen for the treatment of endometriosis
SG10201912141YA (en) Novel dosing regimens of celgosivir for the prevention of dengue
PL3658866T3 (pl) Urządzenie dozujące
HK40008165A (en) Dosage regimen for the treatment of endometriosis
GB201720544D0 (en) Dosage regime
GB201720543D0 (en) Dosage regime